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Abstract
Introduction TNF-like weak inducer of apoptosis (TWEAK) has
been implicated as a mediator of chronic inflammatory
processes via prolonged activation of the NF-κB pathway in
several tissues, including the kidney. Evidence for the
importance of TWEAK in the pathogenesis of lupus nephritis
(LN) has been recently introduced. Thus, TWEAK levels may
serve as an indication of LN presence and activity.
Methods Multicenter cohorts of systemic lupus erythematosus
(SLE) patients and controls were recruited for cross-sectional
and longitudinal analysis of urinary TWEAK (uTWEAK) and/or
serum TWEAK (sTWEAK) levels as potential biomarkers of LN.
The performance of TWEAK as a biomarker for nephritis was
compared with routinely used laboratory tests in lupus patients,
including anti-double stranded DNA antibodies and levels of C3
and C4.
Results uTWEAK levels were significantly higher in LN patients
than in non-LN SLE patients and other disease control groups
(P = 0.039). Furthermore, uTWEAK was better at distinguishing
between LN and non-LN SLE patients than anti-DNA antibodies
and complement levels, while high uTWEAK levels predicted LN
in SLE patients with an odds ratio of 7.36 (95% confidence
interval = 2.25 to 24.07; P = 0.001). uTWEAK levels peaked
during LN flares, and were significantly higher during the flare
than at 4 and 6 months prior to or following the flare event. A
linear mixed-effects model showed a significant association
between uTWEAK levels in SLE patients and their disease
activity over time (P = 0.008). sTWEAK levels, however, were
not found to correlate with the presence of LN or the degree of
nephritis activity.
Conclusions High uTWEAK levels are indicative of LN, as
opposed to non-LN SLE and other healthy and disease control
populations, and reflect renal disease activity in longitudinal
follow-up. Thus, our study further supports a role for TWEAK in
the pathogenesis of LN, and provides strong evidence for
uTWEAK as a candidate clinical biomarker for LN.
AECOM: Albert Einstein College of Medicine; anti-dsDNA Ab: anti-double stranded DNA antibody; AUC: area under the curve; BSA: bovine serum 
albumin; ELISA: enzyme-linked immunosorbent assay; GN: Glomerulonephritis; IP-10: inducible protein 10; LN: lupus nephritis; MCP-1: monocyte 
chemoattractant protein 1; NF: nuclear factor; OA: osteoarthritis; OSS: Ohio SLE Study; PBS: phosphate-buffered saline; r: Spearman rank correla-
tion coefficient; RA: rheumatoid arthritis; ROC: receiver operating characteristic; rSLEDAI: renal Systemic Lupus Erythematosus Disease Activity 
Index; SLE: systemic lupus erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; sTWEAK: serum TNF-like weak inducer 
of apoptosis; TNF: tumor necrosis factor; TWEAK: TNF-like weak inducer of apoptosis; uTWEAK: urinary TNF-like weak inducer of apoptosis.Arthritis Research & Therapy    Vol 11 No 5    Schwartz et al.
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Introduction
Renal involvement in systemic lupus erythematosus (SLE),
known as lupus nephritis (LN), is a common and serious com-
plication, with reports of 5-year renal survival with treatment
ranging from 46 to 95% [1]. LN is characterized by a relaps-
ing- remitting course, requiring constant follow-up and surveil-
lance and often entailing changing treatments. A number of
biochemical markers are currently used to clinically assess
patients' disease activity, such as anti-double-stranded DNA
antibodies (anti-dsDNA Abs) and complement component lev-
els. Nevertheless, the correlation between these markers and
LN is imperfect, and their utility in reflecting disease activity
and in predicting outcome remains controversial [2].
TNF-like weak inducer of apoptosis (TWEAK) is a cytokine
that has drawn much attention since its initial identification in
1997 [3]. TWEAK, and its cognate receptor Fn14, are TNF/
TNF receptor superfamily members, respectively, which have
been found to be involved in many physiological processes,
such as cellular proliferation [4,5], migration [6], survival [7],
differentiation [8], and induction of apoptosis [3,9-11].
TWEAK/Fn14 interactions have also been found to induce
inflammation as they upregulate a number of chemokines,
cytokines and adhesion molecules in various tissues [12,13].
While TWEAK and Fn14 genes are widely expressed, their
expression level is low in normal tissues but is dramatically ele-
vated in the context of injury and disease [14]. Currently it is
thought that TWEAK facilitates physiologic tissue repair and
regeneration following acute injury, but in the setting of
chronic inflammatory diseases the dysregulated expression of
TWEAK is pathogenic [14,15].
Previously we reported that urinary TWEAK (uTWEAK) levels
can reflect LN activity [16]. In the present paper we present
results of further studies performed to elucidate the relation-
ship of uTWEAK to human SLE and LN, and the possible clin-
ical uses of measuring TWEAK levels. To that end, we have
cross-sectionally analyzed uTWEAK levels in a multicenter
cohort of SLE patients with and without documented renal dis-
ease, as well as across several control populations. In addition,
a longitudinal analysis of a prospectively followed group of LN
patients was performed in order to track uTWEAK levels in
individual patients, thereby assessing the ability of uTWEAK to
serve as a clinical marker of disease exacerbation and remis-
sion. We also explore the possible use of other TWEAK meas-
urements, including serum TWEAK (sTWEAK) levels and the
sTWEAK/uTWEAK ratio.
Materials and methods
Patients
The present study was based on three cohorts of patients, all
previously described in detail: the Albert Einstein College of
Medicine (AECOM) lupus cohort, based on patients followed
regularly at lupus clinics in the Jacobi Medical Center and the
Montefiore Medical Center, Bronx, NY, USA [16]; the Ohio
SLE Study (OSS), Columbus, OH, USA [17]; and the Univer-
sity of Southern California patient cohort, including patients
admitted to the Los Angeles County + University of Southern
California Medical Center and seen in consultation by the
Rheumatology Service or seen as outpatients at the Rheuma-
tology Clinics of Los Angeles County + University of Southern
California Medical Center in Los Angeles, CA, USA [18]. The
studies at all participating institutions were approved by their
respective institutional review boards. Informed consent was
obtained from all patients participating in the present study. All
enrolled patients fulfilled at least four of the 1982 revised
American College of Rheumatology criteria for the diagnosis
of SLE [19]. In the three cohorts, all LN patients had under-
gone a kidney biopsy confirming their renal disease histologi-
cally, while all non-LN SLE patients never had documented
renal involvement.
Besides routine clinical laboratory tests performed at the time
of each visit, each patient provided a freshly voided morning
urine specimen and/or blood sample. Urine samples were cen-
trifuged to remove sediment, and serum was aliquoted from
centrifuged blood samples before being frozen at - 80°C.
Two separate studies were performed in this investigation: the
first was a cross-sectional study of both uTWEAK and
sTWEAK in LN patients and controls, while the second was a
longitudinal study of uTWEAK levels in SLE patients over time.
The cross-sectional uTWEAK study included only SLE
patients from the AECOM cohort: 30 biopsy-proven LN
patients with active renal disease at the time of the visit and 49
non-LN SLE patients. In addition to the SLE patients, four
groups of controls were analyzed: healthy controls, 28 individ-
uals with no known history of SLE or any other kidney or
autoimmune disease recruited from a Jacobi Medical Center
obstetrics and gynecology clinic as well as volunteers from the
staff of AECOM; renal controls, 31 patients with kidney dis-
ease due to diabetes (n = 15) or hypertension (n = 16)
recruited from Jacobi Medical Center and Montefiore Medical
Center nephrology clinics; 79 rheumatoid arthritis (RA)
patients, recruited from Jacobi Medical Center and Montefiore
Medical Center rheumatology clinics; and 25 osteoarthritis
(OA) patients, also recruited from Jacobi Medical Center and
Montefiore Medical Center rheumatology clinics.
The cross-sectional sTWEAK analysis was performed based
on patients and controls from the above-described AECOM
cohort who had serum samples drawn at the time of their clinic
visit. Overall, 23 LN patients, 43 SLE non-LN patients, 133
disease controls and 19 healthy individuals were analyzed. In
addition, serum samples of 35 LN patients and 31 non-LN
SLE patients from the University of Southern California cohort
were analyzed for sTWEAK, as well as serum from 20 healthy
control subjects recruited from personnel of the Los Angeles
County + University of Southern California Medical CenterAvailable online http://arthritis-research.com/content/11/5/R143
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and the University of Southern California Keck School of Med-
icine.
The second study was longitudinal, based on data from 13 LN
patients in the OSS cohort. In this cohort, LN subjects were
considered as such only after LN was confirmed by a kidney
biopsy, in addition to these patients having had two or more
SLE flares that required an increase in immunosuppressive
therapy within the past 3 years or having had 4 months of dis-
ease activity despite therapy. The 13 analyzed patients are
unique in that they had a documented visit in which they were
undergoing a LN flare (defined below), in addition to having
regular visits in the months prior to and following the flare
event. A systematic examination of changes in uTWEAK levels
before, during and following the flare was therefore possible.
In a separate analysis, these OSS patients were combined
with 31 SLE patients from the AECOM cohort (18 patients
with LN and 13 patients without evidence of nephritis) on
whom longitudinal data were available, to examine the relation-
ship between uTWEAK levels and disease activity over time.
Classification of systemic lupus erythematosus activity 
status
LN activity was evaluated based on a subset of the Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) 2000
[20], designated the renal Systemic Lupus Erythematosus
Disease Activity Index (rSLEDAI). The rSLEDAI consists of the
four kidney-related items of the SLEDAI 2000, including hema-
turia (>5 red blood cells/high-power field), pyuria (>5 white
blood cells/high-power field), proteinuria (>0.5 g/24 hours or
urine protein/creatinine ratio >0.5) and urinary casts (heme,
granular, or red blood cell). The presence of each of the
parameters is scored as 4 points; the renal activity score can
therefore range from 0 to 16. For our inclusion criteria, any
rSLEDAI score >0 was considered as active LN, unless other-
wise specified.
Systemic lupus activity was scored with the original SLEDAI
2000. OSS patients were additionally classified regarding the
presence and severity of a renal flare, based on predefined
increases in urine sediment, serum creatinine levels and pro-
teinuria from their baseline levels, as described previously in
detail by Rovin and colleagues [17,21].
TWEAK measurement
TWEAK levels in serum and urine were determined by ELISA,
as described previously [16]. Briefly, microtiter plates were
coated with the BEB3 murine monoclonal anti-TWEAK anti-
body [7] in bicarbonate buffer overnight. The plates were then
blocked with 3% BSA/PBS for 6 hours, washed, and urine
samples diluted 1:3 or serum samples diluted 1:15 in 3%
BSA/PBS were added in duplicate. Serial dilutions of recom-
binant soluble human TWEAK [7] were also added to the
plates, enabling construction of a standard curve. Following an
overnight incubation at 4°C, the plates were washed, and a
solution of pre-mixed biotinylated murine anti-TWEAK anti-
body P5G9 [13] and avidin- horseradish peroxidase was
added for 1 hour at room temperature. Finally, the plates were
washed and a developer solution was added. TWEAK levels
were derived from an average of the duplicate assays that
were carried out for all samples. All assays were performed
blindly, without knowledge of the patient's identity, disease
presence or disease activity.
Assay standardization
To take into account variations in urine concentration,
uTWEAK levels were corrected to urine creatinine, when lev-
els of the latter were available. Corrected uTWEAK levels are
therefore expressed as picograms per milligram of creatinine
(pg/mgCr); otherwise, uTWEAK levels, as well as sTWEAK
levels, are expressed as picograms per milliliter (pg/ml).
The C3, C4 and anti-dsDNA Ab measurements obtained at
different centers and measured in different laboratories were
standardized by dividing the value received for each patient by
the mid-normal range of the measuring laboratory.
Statistical analysis
The data were not normally distributed, so median values and
interquartile ranges were calculated as measures of central
tendency; the data are therefore expressed as the median
(interquartile range), unless otherwise indicated. The Mann-
Whitney U test was used to compare between two groups
and the Kruskal- Wallis test was utilized for comparing three or
more groups. The Kruskall-Wallis test was followed by Dunn's
post-hoc testing. Proportions were compared by the two-sam-
ple test of proportions. Association among categorical varia-
bles was measured by Pearson's chi-squared test.
Correlations were performed using the Spearman rank corre-
lation coefficient, followed by Sidak adjustment for signifi-
cance levels to account for multiple comparisons.
Area under the curve (AUC) calculations of nonparametric
receiver operating characteristic (ROC) curves were used to
compare the ability of the various biomarkers to distinguish
between specific groups of patients. In addition, sensitivity
and specificity characteristics were derived from the ROC
curves and were used to identify cutoff point values for defin-
ing high and low TWEAK levels.
Logistic regression was performed on the cross-sectional
data, and the odds ratio was derived. Longitudinal data from
the OSS were log-transformed and analyzed using repeated-
measures analysis of variance, followed by Dunn's post-hoc
testing for nonparametric data; these data were graphed using
a least-squares means plot. A linear mixed-effects model was
constructed based on longitudinal data from the OSS and
AECOM cohorts to examine the relationship between TWEAK
levels and patients' disease activity over time. P < 0.05 wasArthritis Research & Therapy    Vol 11 No 5    Schwartz et al.
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considered significant. The statistics programs used for the
analysis were Intercooled Stata version 9.2 (StataCorp LP,
College Station, TX, USA) and GraphPad Prism version 4.03
(GraphPad Software, San Diego, CA, USA).
Results
Urinary TWEAK is a marker of lupus nephritis
The demographic characteristics of the different groups
included in this cross-sectional analysis of uTWEAK are pre-
sented in Table 1. In all groups but the renal controls, more
than 85% of the individuals were women. As might be
expected, the RA patients, OA patients and renal controls
were older than both SLE patient groups and healthy individu-
als. Creatinine levels in the lupus and control groups were as
follows: LN patients, 0.85 (0.6 to 1.2); SLE non-LN patients,
0.7 (0.6 to 0.8); RA patients, 0.8 (0.7 to 0.9); OA patients, 0.8
(0.7 to 0.9); and renal patients, 2.3 (1.7 to 3.3). Patients in the
RA group did not have associated renal involvement, as seen
by their normal creatinine levels, and the normal urinalyses
obtained around the time of the sample for uTWEAK in the
large majority of RA patients for which these were performed.
As compared with the patients with LN, the renal control group
had significantly higher creatinine levels (P < 0.001), while
those in the SLE non-LN group were lower (P = 0.004). The
LN and non-LN groups, however, were similar in terms of age,
sex and ethnicity.
uTWEAK levels in each of the experimental groups were as fol-
lows: LN patients, 12.98 (5.76 to 30.19); SLE non-LN
patients, 6.06 (1.77 to 12.83); normal controls, 5.48 (1.21 to
9.94); RA patients, 6.90 (1.79 to 15.61); OA patients, 4.75
(0.78 to 16.55); and renal patients, 6.04 (2.93 to 17.27). A
multigroup comparison between uTWEAK levels of LN
patients and the individual control groups yielded an overall
significant difference (P = 0.039). Post-hoc testing revealed
statistically significant lower uTWEAK levels in the SLE non-
LN patient (P = 0.005), healthy control (P = 0.003), and RA
patient (P = 0.013) groups, compared with the LN group (Fig-
ure 1).
Interestingly, renal disease per se did not independently raise
uTWEAK levels, as there was no significant difference
between uTWEAK levels of the renal controls compared with
all other non-renal control groups (non-LN SLE patients,
healthy controls, RA patients and OA patients) (6.04 (2.93 to
17.27) pg/ml vs. 5.85 (1.64 to 13.71) pg/ml, respectively; P =
0.313) - suggesting it is the combination of renal disease and
SLE that leads to high uTWEAK levels. In addition, we found
that high uTWEAK levels are a specific characteristic of LN
and are not a general feature of SLE, as uTWEAK levels of
non-LN SLE patients were not significantly different from
those of the non-SLE controls (6.06 (1.77 to 12.83) pg/ml vs.
5.84 (1.84 to 14.26) pg/ml, respectively; P = 0.851).
Urinary TWEAK differentiates between lupus nephritis 
and nonlupus nephritis systemic lupus erythematosus 
patients
We examined whether uTWEAK levels in LN patients
remained significantly higher than that in non-LN SLE patients
(using the same patients studied for Figure 1) even when
uTWEAK is corrected to urinary creatinine. Indeed, when nor-
malized to urinary creatinine, the median uTWEAK level of
patients with active, biopsy-proven LN was 12.54 (5.00 to
19.38) pg/mgCr, while that of non-LN SLE patients was 5.02
(1.94 to 9.11) pg/mgCr (P < 0.001) (Figure 2a). As seen in
Table 1, there is a significant difference in disease activity
Table 1
Cross-sectional study demographics
LN patients Non-LN 
patients
Normal 
controls
Rheumatoid 
arthritis 
patients
Osteoarthritis 
patients
Renal controls P value all 
(LN vs. non-
LN)
Number of 
patients 
(% female)
30 (93) 49 (88) 28 (89) 79 (90) 25 (84) 31 (55) - (0.474)
Age (years) 34.5 (28 to 44) 41 (34 to 46) 37 (29 to 45) 58 (51 to 67) 63 (57 to 77) 63 (56 to 67) <0.001* 
(0.074)
Ethnicitya 14/14/0/2 27/17/0/2b 7/14/3/4 - - - -
African 
American (%)
46.6 58.7 25 - - - - (0.304)
SLEDAI 10 (7 to 16) 3.5 (2 to 6) - - - - - (<0.001*)
SLEDAI without 
renal 
component
2 (0 to 6) - (0.426)
Continuous variables presented as the median (interquartile range). LN, lupus nephritis; SLEDAI, Systemic Lupus Erythematosus Disease Activity 
Index. aAfrican American/Hispanic/Caucasian/other.bEthnicity of three additional non-LN systemic lupus erythematosus patients is unknown. *P < 
0.05. The Mann- Whitney U test was used to compare two groups with continuous variables, while the Kruskal- Wallis test was used for three or 
more groups. The two-sample proportion test was used for categorical variables.Available online http://arthritis-research.com/content/11/5/R143
Page 5 of 10
(page number not for citation purposes)
between the two SLE groups, since only patients with active
renal disease (rSLEDAI ≥ 4) were included in the LN group.
On the other hand, none of the non-LN patients, by definition,
had any renal score in the SLEDAI, thus reducing the non-LN
group's SLEDAI potential maximal score.
In an effort to isolate the effect of the nephritis on uTWEAK lev-
els as opposed to general disease activity, we compared
uTWEAK levels of LN patients and non-LN patients with an
identical overall SLEDAI score of 4 (six LN patients and eight
non-LN SLE patients). Under these circumstances, uTWEAK
levels were also significantly higher in the LN group than in the
non-LN group (13.60 (5.95 to 17.03) pg/mgCr vs. 2.77 (1.96
to 7.30) pg/mgCr, respectively; P = 0.008) - indicating that it
is the nephritis and not systemic disease activity that raises
uTWEAK levels. Furthermore, as shown in Figure 2b, and as
similarly reported [16], it is the degree of activity of the renal
disease that dictates uTWEAK levels, as a significant associ-
ation was found between LN activity as measured by the
rSLEDAI, and uTWEAK (r = 0.388, P = 0.047).
A nonparametric ROC curve, constructed to quantify how well
uTWEAK distinguishes between SLE patients with or without
nephritis, has an AUC of 0.724 (P < 0.001; Figure 2c). Inter-
estingly, clinically used markers such as anti-dsDNA Ab, C3
and C4 within the same cohort of patients did not have the
same discriminatory power (AUC of anti-dsDNA Abs = 0.599,
P = 0.152; C3 = 0.577, P = 0.258; and C4 = 0.631, P =
0.053).
We dichotomized uTWEAK based on the above ROC curve,
choosing a cutoff point of 13 pg/mgCr with a specificity of
90% and a sensitivity of 50%. We validated this cutoff point
by testing its discriminating ability on a nonoverlapping cohort
of patients described previously [16]. Indeed, using this cutoff
point on the previous cohort we found a statistically significant
association between patients being classified as having a high
or low uTWEAK level and the presence of LN (P = 0.045). A
logistic regression model adjusting for age, sex and ethnicity
based on our current cohort showed an odds ratio of 7.36
(95% confidence interval = 2.25 to 24.07, P = 0.001) for high
uTWEAK levels, correlating with the presence of LN.
To assess whether uTWEAK might be used to confirm a diag-
nosis of LN made based on clinical grounds alone, we com-
pared uTWEAK levels of 30 patients with biopsy-proven LN
and 11 SLE patients with a laboratory-based diagnosis of LN
but with no confirming renal biopsy. In an attempt to ensure
these latter patients indeed had LN and not just a concomitant
renal abnormality, we only included patients with rSLEDAI
scores ≥ 8 (requiring the presence of at least two out of the
four abnormal renal disease parameters measured by the
rSLEDAI). As predicted by our hypothesis, uTWEAK levels did
not differ significantly between the two groups (P = 0.941;
Figure 2d).
While high uTWEAK levels appear to be a feature of LN, no
significant differences in uTWEAK were detected between dif-
ferent World Health Organization classes of glomerulonephri-
tis (GN) found at biopsy (P = 0.412 in a comparison of classes
III, IV and V).
Urinary TWEAK is a marker of lupus nephritis activity
For the second part of the present study, we monitored and
analyzed uTWEAK levels as a function of patient disease activ-
ity over time, including patients from both the AECOM and the
OSS cohorts. As shown in Table 2, the analyzed patients from
these two geographically distinct cohorts were relatively com-
parable, both in terms of their demographic parameters (age
and sex) and of their disease activity (as measured by rSLEDAI
scores, serum creatinine levels and World Health Organiza-
tion class). The main difference between the groups was that
the AECOM cohort also included patients without LN, and so
the analysis included an appropriate adjustment for the pres-
ence of LN.
The group of 13 patients from the OSS cohort was unique in
that the patients had undergone a LN flare during their routine
bi-monthly follow-up. Urine samples from before, during and
after the flare were therefore prospectively collected. As
shown in Figure 3, uTWEAK levels peaked during the flare,
gradually increasing before and decreasing after the flare. Sta-
Figure 1
Systemic lupus erythematosus patients with lupus nephritis have high  urinary TWEAK Systemic lupus erythematosus patients with lupus nephritis have high 
urinary TWEAK. A multigroup comparison between urinary TNF-like 
weak inducer of apoptosis (uTWEAK) levels of 30 patients with biopsy-
proven lupus nephritis (LN), 49 systemic lupus erythematosus (SLE) 
patients without LN, 28 healthy individuals, 79 rheumatoid arthritis (RA) 
patients, 25 osteoarthritis (OA) patients and 31 renal controls (P = 
0.039). *P < 0.05 in two-group post-hoc comparisons with LN. Graphs 
represent median levels with the interquartile range.Arthritis Research & Therapy    Vol 11 No 5    Schwartz et al.
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tistically significant differences were found between uTWEAK
levels at flare as compared with 4 and 6 months before and
after the flare timepoint (± 4 months, P = 0.035 and P =
0.025, respectively; ± 6 months, P = 0.017 for both time-
points). In addition, although the differences between
uTWEAK levels at flare and at ± 2 months did not reach sta-
tistical significance, a clear trend in a similar direction is
observed.
To analyze a larger sample of patients, we combined the lon-
gitudinal data of these 13 patients from the OSS cohort with
data from a group of 31 unselected SLE patients from the
AECOM cohort on whom serial measurements of uTWEAK
levels had been obtained. (As most of these AECOM patients
did not flare during the follow-up, these data were not included
in the previous analysis.) A linear mixed-effects model using
both the OSS and AECOM patient groups was constructed,
with adjustments made for age, sex, ethnicity, and the pres-
ence of LN. This model showed a statistically significant asso-
ciation between uTWEAK levels of patients and their renal
disease activity over time (β = 0.074, 95% confidence interval
= 0.020 to 0.129, P = 0.008).
Figure 2
High urinary TWEAK is characteristic of lupus nephritis in systemic lupus erythematosus patients High urinary TWEAK is characteristic of lupus nephritis in systemic lupus erythematosus patients. (a) Thirty lupus nephritis (LN) patients have signif-
icantly higher urinary TNF-like weak inducer of apoptosis (uTWEAK) levels (corrected to creatinine) than 49 systemic lupus erythematosus (SLE) 
patients without LN (P < 0.001). (b) uTWEAK levels of 78 SLE patients (both LN patients and non-LN patients) correlate significantly with renal 
Systemic Lupus Erythematosus Disease Activity Index (rSLEDAI) scores (r = 0.388, P = 0.047). (c) Nonparametric receiver operating characteristic 
(ROC) curve for uTWEAK and the presence of LN in SLE patients; area under the curve = 0.724. (d) uTWEAK levels in 30 patients with biopsy-
proven LN versus 11 SLE patients with a clinical diagnosis of LN not confirmed by renal biopsy (P = 0.941). Graphs represent median levels with 
the interquartile range. **P < 0.01.Available online http://arthritis-research.com/content/11/5/R143
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Serum TWEAK levels and the urine/serum TWEAK ratio 
are not better markers than urinary TWEAK
A cross-sectional analysis of sTWEAK levels of SLE patients
and controls was performed to test its biomarker function. To
that end, available serum samples from 66 SLE patients (23
LN patients and 43 non-LN patients) and from 19 controls
(healthy controls) from the AECOM cohort were analyzed for
TWEAK levels. The sTWEAK data for 66 University of South-
ern California cohort SLE patients (35 LN patients and 31
non-LN patients) and for 20 healthy controls were also ana-
lyzed. Since the findings from both cohorts were similar, we
present in detail only the data from the AECOM cohort (Table
3).
The only significant finding in this cross-sectional analysis
comparing sTWEAK levels of SLE patients and controls is that
sTWEAK levels are significantly lower in SLE patients than in
healthy individuals. Interestingly, similar findings that sTWEAK
levels are lower in patients with renal disease than in healthy
controls have been reported in the literature [22,23]. Never-
theless, this difference is not sufficient for sTWEAK to serve
as a discriminating marker between healthy individuals and
SLE patients, as the AUC of the constructed ROC curve was
0.660 and the sensitivity and specificity calculations were sig-
nificantly inferior to those of anti-nuclear and anti-dsDNA Ab
levels.
Table 2
Longitudinal study patient demographics
AECOM cohort OSS cohort P value
Number of patients (% female) 31 (81) 13 (100) 0.091
Lupus nephritis (%) 58 100 0.005*
Number of visits per patient 3 (2 to 5) 3 (2 to 5) 0.508
Time between visits (months) 3 (2 to 6) 2 (2 to 6)
Ethnicitya 18/12/0/1 5/0/8/0
African American (%) 58 38 0.235
Age at first visit (years) 36 (31 to 44) 30 (28 to 36) 0.089
rSLEDAIb 4 (0 to 8) 4 (0 to 4)
World Health Organization classb, n (%)
III 6 (33) 1 (8) 0.092
IV 9 (50) 9 (69) 0.284
V 2 (11) 3 (23) 0.371
VI 1 (6) 0 (0) 0.388
Serum creatinine levels 0.8 (0.7 to 1.0) 1.0 (0.8 to 1.6)
Only lupus nephritis patients 0.9 (0.7 to 1.1)
At first visitb 0.8 (0.7 to 1.2) 1.03 (0.8 to 1.5) 0.160
Continuous variables presented as the median (interquartile range). AECOM, Albert Einstein College of Medicine; OSS, Ohio SLE Study; 
rSLEDAI, renal Systemic Lupus Erythematosus Disease Activity Index. aAfrican American/Hispanic/Caucasian/other.bLupus nephritis patients 
only. *P < 0.05. Continuous variables were compared by the Mann- Whitney U test, while the two-sample proportion test was used for categorical 
variables. Statistical comparisons were not performed when values were not independent of each other.
Figure 3
Urinary TWEAK levels at different timepoints relative to a lupus nephri- tis flare Urinary TWEAK levels at different timepoints relative to a lupus nephri-
tis flare. Urinary TNF-like weak inducer of apoptosis (uTWEAK) levels of 
13 lupus nephritis (LN) patients followed in the Ohio SLE Study cohort, 
taken 6, 4 and 2 months before and after a LN flare, including at the 
time of the flare itself (timepoint 0). Graph represents least-squares 
(LS) means with standard error. *P < 0.05 compared with uTWEAK 
level at flare.Arthritis Research & Therapy    Vol 11 No 5    Schwartz et al.
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Since we found that uTWEAK is higher and sTWEAK is lower
in SLE patients compared with healthy controls, we investi-
gated whether the ratio of uTWEAK to sTWEAK may repre-
sent a better biomarker than uTWEAK alone. Nevertheless,
while the uTWEAK/sTWEAK ratio performed similarly to
uTWEAK alone in several analyses, it did not correlate signifi-
cantly with cross-sectional disease activity as reflected by the
rSLEDAI. Moreover, the AUC of the ROC curve testing the dif-
ferentiating ability of the uTWEAK/sTWEAK ratio between LN
patients and non-LN SLE patients was 0.673, worse than
uTWEAK alone.
Discussion
Recent findings have linked TWEAK to renal inflammation in
an animal model of SLE [13,24], and on this premise we
hypothesized that excreted uTWEAK may denote the pres-
ence and activity level of LN in SLE patients. Previously we
determined that uTWEAK levels of LN patients are higher than
those of non-LN SLE patients, and that uTWEAK levels corre-
late significantly with renal disease activity [16]. In our present
study, high uTWEAK levels were found to reflect the presence
of LN in SLE patients even better than clinical markers in wide-
spread use, such as anti-dsDNA Ab and complement compo-
nent levels. In fact, high uTWEAK levels in SLE patients
correlate with sevenfold increased odds of LN. We observed
that LN patients have higher uTWEAK levels than several other
control groups analyzed, indicating that high uTWEAK levels
are a relatively unique feature of LN and are neither due to the
systemic inflammatory process (as occurs in non-LN SLE
patients or in RA patients) nor the renal disease in isolation.
Since the comparison of uTWEAK levels between the renal
and nonrenal lupus groups in patients with identical SLEDAI
scores did not include many patients in each group, however,
it would be interesting to repeat this particular analysis in a
larger study. Nevertheless, the correlation we found between
uTWEAK levels and the severity of renal disease supports our
conclusion that high uTWEAK levels in lupus patients primarily
reflect renal activity. Furthermore, fluctuations of uTWEAK lev-
els were found to reflect renal disease activity in LN patients
over time, thus potentially serving as a helpful biomarker in the
clinical follow-up.
It is interesting to consider whether any particular medication
used in our patients may have contributed to variations in
uTWEAK production. In previous work, however, we did not
find any correlation between treatment with prednisone and
other immunosuppressive drugs used to treat nephritis, and
uTWEAK levels [16]. Nevertheless, this question is worthy of
a more comprehensive analysis - in particular, focusing on
whether effective therapy lowers uTWEAK levels over time.
These studies are in progress. Finally, while in our study we did
not find a difference in uTWEAK levels between the various
World Health Organization stages of LN, particularly between
the proliferative (class III, class IV) and membranous (class V)
classes, this finding remains to be confirmed in larger numbers
of patients displaying each of these histological subtypes.
The need for a reliable clinical biomarker for LN cannot be
overstated. It is well established that long-term survival in SLE
can be improved with early diagnosis and prompt treatment of
the renal disease [25]. Nevertheless, the usually insidious
onset and fluctuating nature of LN can make early identifica-
tion and follow-up very difficult. While renal biopsy is the gold
standard for the diagnosis and assessment of nephritis in
lupus patients, it is an invasive procedure that is not generally
performed serially for monitoring purposes. Anti-DNA Abs and
complement levels are routinely followed in lupus patients but,
while often correlating with the presence of active renal dis-
ease, these serologic parameters are not specific for this man-
ifestation and their performance as nephritis biomarkers is not
optimal [2,26-28]. In the absence of specific markers for LN,
clinicians rely upon laboratory tests reflecting renal function,
such as urinalysis, urinary protein measurements, blood urea
nitrogen and serum creatinine. These measurements are use-
ful in monitoring chronic renal processes, but abnormal levels
may occur relatively late in the inflammatory course.
A number of potential biomarkers have been described in the
past few years, although none has yet been validated [26].
Among the more promising suggested biomarkers are the
chemokines inducible protein 10 (IP-10) and monocyte chem-
oattractant protein 1 (MCP-1). Active SLE patients were
shown to have increased levels of IP-10, as opposed to non-
active SLE patients, RA patients and healthy controls [29,30].
Moreover, it has been reported that IP-10 mRNA levels iso-
lated from urine cells can distinguish diffuse proliferative GN
from other classes of LN [31]. MCP-1 has also been impli-
cated in the pathogenesis of LN and suggested as a potential
Table 3
Serum TWEAK results for the Albert Einstein College of Medicine cohort (pg/ml)
Serum TWEAK P value AUC of ROC curve
SLE patients vs. healthy controls 15.87 (13.04 to 24.36), n = 66 vs. 23.56 (17.26 to 27.12), n = 19 0.034* 0.660
SLE + LN patients vs. SLE non-LN patients 16.42 (13.09 to 24.71), n = 23 vs. 15.72 (12.81 to 24.30), n = 43 0.747 -
Continuous variables presented as the median (interquartile range). LN, lupus nephritis; SLE, systemic lupus erythematosus The area under the 
curve (AUC) was calculated from nonparametric receiver operating characteristic (ROC) curves constructed to test the ability of serum TNF-like 
weak inducer of apoptosis (TWEAK) to distinguish between patients and healthy controls. *P < 0.05. The Mann- Whitney U test was used to 
compare between two groups.Available online http://arthritis-research.com/content/11/5/R143
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biomarker by Rovin and colleagues, who demonstrated that
urinary levels of MCP-1 may predict impending flare, flare
severity and response to treatment. Similar to our findings
regarding uTWEAK, however, MCP-1 was not reported to pre-
dict renal histopathology [17]. Of note, both IP-10 and MCP-
1 are among the proinflammatory chemokines induced by
TWEAK in mesangial [13,32] and tubular [33] renal cells.
In our longitudinal study, although uTWEAK levels did
increase as the flare approached, the peak was at the time of
the flare rather than in advance of it. As the measurements
were based on a relatively small group of 13 patients, how-
ever, it is possible that there was simply not enough power to
be conclusive on this point. While under the limitations of our
study TWEAK was not found to be predictive of the flare, an
increase in uTWEAK levels at the time of the flare may there-
fore be able to provide supporting evidence if the diagnosis of
a flare is in doubt.
uTWEAK levels of biopsy-proven LN patients were not differ-
ent from those of patients diagnosed clinically with LN yet
were significantly higher than those of non-LN patients, imply-
ing that high uTWEAK levels support the diagnosis of LN - per-
haps circumventing the need in some patients for a diagnostic,
yet invasive, biopsy. Nevertheless, uTWEAK levels do not dis-
tinguish between different World Health Organization GN
classes among LN patients, and therefore cannot entirely
replace kidney biopsy in the diagnostic process.
Certain limitations encountered in our study should be
addressed in the future, foremost of which is our inability to
compare the performance of uTWEAK with proteinuria, the
traditional measure that is used. As our definition of LN was
based on proteinuria, we could not examine proteinuria as an
independent marker in comparison with uTWEAK. Future
studies including an additional disease activity index - such as
the British Isles Lupus Assessment Group (BILAG) [34], for
example- would be a means of further validating the presented
results before clinical application.
A potential role for TWEAK in LN has been explored experi-
mentally in vitro and in vivo. As mentioned, TWEAK has been
found to induce secretion of known chemokine mediators of
SLE, such as MCP-1, IP-10 and RANTES [13,33]. In addition,
TWEAK/Fn14 interaction induces prolonged NF-κB activation
in human renal mesangial cells [32], and it is now thought that
prolonged activation of this route underlies chronic inflamma-
tory diseases [15]. Specific to LN, Zhao and colleagues dem-
onstrated that TWEAK plays an important role in the murine
chronic graft versus host model of LN, such that Fn14-knock-
out mice, or mice treated with anti-TWEAK monoclonal anti-
bodies, exhibited reduced inflammation and less severe
nephritis [24].
Since uTWEAK but not other urinary proteins correlate with
renal disease [16], and since urine but not serum levels are
elevated, high uTWEAK levels seem to reflect high local renal
production rather than increased total urine protein. Moreover,
in our study uTWEAK levels were clearly not a reflection of
renal function, since uTWEAK levels in patients with LN were
higher than in non-LN patients with both significantly higher
(renal disease group) and lower (non-LN SLE group) serum
creatinine levels (Figure 1). Accordingly, the increased levels
of uTWEAK and their correlation with renal disease activity
over time represent increased renal expression of TWEAK at
the time of the nephritis process, providing additional evidence
for the role of TWEAK in the pathogenesis of LN.
Conclusions
The relapsing- remitting course of LN, among the most serious
complications of SLE, requires close monitoring and often fre-
quent treatment adjustments throughout patients' lives. Kidney
biopsy, however, is impractical as a clinical surveillance tool. A
dependable biomarker that can reflect the patient's renal dis-
ease activity is therefore highly desirable. We show here that
uTWEAK can serve as a biomarker of LN, both as a one-time
measurement and as a means of monitoring individual patients
over time. Moreover, uTWEAK performed significantly better
than traditional biomarkers in widespread use (anti-dsDNA
Abs, C3 and C4) in distinguishing between lupus patients with
and without nephritis. Analysis of uTWEAK levels in an
expanded panel of patients followed longitudinally with partic-
ular focus on measurements prior to clinical evidence of dis-
ease activity as well as correlations with patients' response to
a given therapy, together with measurements of other emerg-
ing biomarkers, will help define a role for the serial measure-
ment of uTWEAK levels in the clinical management of lupus
patients with suspected or existing renal involvement. Finally,
uTWEAK levels may also be useful in the future to identify
potential candidates for therapies intended to block the
TWEAK signaling pathways [8,24].
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